KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cognex (CGNX) Research & Development (2016 - 2025)

Cognex (CGNX) has disclosed Research & Development for 17 consecutive years, with $36.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 10.82% year-over-year to $36.1 million, compared with a TTM value of $139.0 million through Dec 2025, down 0.6%, and an annual FY2025 reading of $139.0 million, down 0.6% over the prior year.
  • Research & Development was $36.1 million for Q4 2025 at Cognex, up from $35.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $38.5 million in Q2 2023 and bottomed at $31.3 million in Q3 2021.
  • Average Research & Development over 5 years is $34.7 million, with a median of $34.7 million recorded in 2023.
  • The sharpest move saw Research & Development increased 14.01% in 2021, then fell 6.57% in 2023.
  • Year by year, Research & Development stood at $35.5 million in 2021, then grew by 4.64% to $37.1 million in 2022, then decreased by 6.57% to $34.7 million in 2023, then fell by 6.21% to $32.5 million in 2024, then rose by 10.82% to $36.1 million in 2025.
  • Business Quant data shows Research & Development for CGNX at $36.1 million in Q4 2025, $35.1 million in Q3 2025, and $33.1 million in Q2 2025.